Jiangsu province’s healthcare security administration has released a list identifying drugs subject to dual channel management and separate payment, focusing on those added to the National Reimbursement Drug List (NRDL) through negotiations this year. A total of 74 drugs fall under “dual channel” management, with 36 designated for separate payment.
In accordance with the “Handling procedures for National NRDL Drug Dual Channel Management and Separate Payment Drug” regulations in Jiangsu, expenses for nationally insured patients using separate payment drugs under “dual channel” management, whether as outpatients or during hospitalization, will be settled based on provincial or city drug payment ratios. If these ratios are lower than the current basic medical insurance settlement standards, the higher standard will apply. For non-separate payment drugs under “dual channel” management, existing local regulations will be enforced.- Flcube.com
